Terremoto Biosciences secures $175m in series B funding, total capital hits $250m By Investing.com
2 min read
© AKUURA.
Terremoto Biosciences has successfully raised $175 million in a Series B funding round, taking its total capital to $250 million. The recent funding was contributed by new investors EcoR1 Capital, Novo Holdings, and Cormorant Capital, alongside existing investors OrbiMed and Third Rock Ventures.
The biotech firm plans to use the fresh capital to bolster its platform and expedite numerous in-house programs aimed at addressing diseases with high unmet medical needs. Terremoto is currently developing small-molecule medicines for a broad spectrum of severe diseases, targeting both known and previously undrugged targets.
CEO Peter Thompson expressed gratitude for the investor support during what he described as a challenging time in the biotech sector. He highlighted that their strategy allows the company to deliver best-in-class therapies and first-in-class medicines, demonstrating the strength of its management team as Terremoto embarks on its next phase of growth.
By expanding its covalent alphabet, Terremoto Biosciences is aiming to lead in the development of novel treatments for severe diseases, reinforcing its commitment to delivering innovative solutions in the healthcare sector.
InvestingPro Insights
The financial outlook for Terremoto Biosciences appears promising according to InvestingPro. The company has seen a significant uptick in its market cap, which is now sitting at a robust $39.36 billion. This is supported by a strong P/E ratio of 508.81, indicating high investor expectations for future earnings.
InvestingPro Tips highlights the company’s consistent increase in earnings per share and an expectation of net income growth this year. Additionally, two analysts have revised their earnings upwards for the upcoming period, further bolstering confidence in Terremoto Biosciences.
In terms of performance, the company has seen a strong return over the last month and year, trading near its 52-week high. However, it should be noted that the company is trading at a high price-to-book multiple of 6.8, which could indicate overvaluation.
In light of these insights, readers interested in more detailed analysis and additional tips should consider the InvestingPro product, which boasts a total of 13 relevant tips for Terremoto Biosciences.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
